Japanese Demand For Anti-Smoking Drug Outpaces Pfizer Supplies
This article was originally published in PharmAsia News
Executive Summary
A sudden, but expected Japanese demand for its smoking-cessation drug caught U.S.-based Pfizer shorthanded with supplies of its Champix (varenicline)